Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery

Documenti analoghi

• Reduced prandial insulin secretion contributes to prandial hyperglycaemia in non‐diabetic individuals with spinal cord injury
  di: Michelle Trbovich, et al.
  Pubblicazione: (2025)
• Association between recent exposure to continuous glucose monitoring‐recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes
  di: Cecilie H. Svensson, et al.
  Pubblicazione: (2024)
• Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
  di: Jason M. Samuels, et al.
  Pubblicazione: (2024)
• Insulin Sensitive Patients With Impaired Glucose Tolerance: Physiologic and Metabolic Characterization ( STOP DIABETES )
  di: John Armato, et al.
  Pubblicazione: (2026)
• Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
  di: Irl B. Hirsch, et al.
  Pubblicazione: (2024)